Jetstream Venture Fund Invests in Rejuvenation Technologies, Expanding its Expanding Longevity and Regenerative Medicine Portfolio
Jetstream Venture Fund Invests in Rejuvenation Technologies, Expanding its Expanding Longevity and Regenerative Medicine Portfolio
PR Newswire
SCOTTSDALE, Ariz., Sept. 24, 2026
SCOTTSDALE, Ariz., Sept. 24, 2026 /PRNewswire/ -- Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider mainstream audience, today announced a strategic investment in Rejuvenation Technologies. The biotechnology company is pioneering targeted mRNA therapies designed to extend telomeres, aiming to restore cellular regenerative capacity and treat severe age-related diseases.
This addition solidifies Jetstream's position at the forefront of longevity science, life extension, and advanced gene therapy. Rejuvenation Technologies joins recent Jetstream portfolio additions Rejuvenate Bio (a Harvard-spun gene therapy company backed by Merck Animal Health), and Wonderlab Bio, a pioneer in off-the-shelf cell therapies. Together, these investments create a cohesive, high-growth portfolio, granting everyday retail investors access to the future of human healthspan and cellular repair.
Born out of foundational research at Stanford University by CEO and co-inventor Dr. John Ramunas, Rejuvenation Technologies utilizes modified mRNA delivered via proprietary lipid nanoparticles to specific organs. Unlike permanent telomerase activation, this transient approach temporarily extends telomeres to reverse years of cellular aging in a single day.
Backed by top-tier institutional investors, including Khosla Ventures and Y Combinator, and supported by over $8 million in non-dilutive grants from the NIH and CIRM, the company is rapidly advancing preclinical pipelines targeting idiopathic pulmonary fibrosis and severe chronic liver disease.
"Rejuvenation Technologies represents the kind of highly technical, paradigm-shifting science Jetstream seeks to identify early," said Chris Yoo, Fund Manager at Jetstream. "By adding their breakthrough mRNA platform alongside our existing stakes in Rejuvenate Bio and Wonderlab Bio, we are thrilled to offer our investors a seat at the table for disruptive technologies that could fundamentally alter how we treat chronic, age-related diseases."
By securing early-stage access to companies addressing massive gaps in regenerative medicine, Jetstream continues to break down the barriers of venture capital to everyday investors.
About Jetstream Venture Fund Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC, seeking to provide investors access to high-growth companies with lower minimums and no carried interest. To learn more or view current portfolio data, visit https://www.jvf.vc.
Disclosure: Investors should carefully consider the investment objectives, risks, charges, and expenses before investing. The prospectus contains this information and can be obtained by visiting https://www.jvf.vc. Please read carefully before investing.
Media Contact: Dawson Fearnow, dawson@mmprmarketing.com
SOURCE Jetstream Venture Fund
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States